Replimune Group (REPL) News Today

Replimune Group, Inc. (NASDAQ: REPL) shares declined after a mix of neutral updates and negative developments, including disappointing quarterly results and multiple class‐action lawsuit notices. Below are the key items impacting investor sentiment:

• Neutral Sentiment: Seeking Alpha analyzes the company’s prospects for FDA approval after a recent trial rejection, highlighting potential pathways and hurdles ahead. Replimune Group: The Prospects For FDA Approval After Rejection
• Neutral Sentiment: MarketBeat reports that Replimune is expected to announce its Q1 2026 earnings before the market opens on August 14, keeping investors focused on upcoming financials. Replimune Group (REPL) Expected to Announce Earnings on Thursday
• Neutral Sentiment: Replimune released its fiscal first quarter 2026 results and provided a corporate update, detailing R&D progress on its oncolytic immunotherapies alongside cash runway and pipeline milestones. Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: The company’s Q1 loss widened to $0.95 per share, missing consensus by $0.12 and representing a 61% year-over-year increase in losses. Replimune (REPL) Q1 Loss Widens 61%
• Negative Sentiment: Levi & Korsinsky, LLP has notified investors of a class-action securities lawsuit against Replimune Group, Inc., setting a lead plaintiff deadline of September 22, 2025. Shareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights
• Negative Sentiment: The Gross Law Firm filed a notice of securities-law violations against Replimune, urging shareholders to discuss their rights before the September 22, 2025 deadline. Replimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights
• Negative Sentiment: Bronstein, Gewirtz & Grossman LLC alerted investors with significant losses about the opportunity to lead a class-action suit against the company. REPL Investor Alert: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
• Negative Sentiment: Rosen Law Firm, the first to file, reminded purchasers of REPL securities of the importance of securing counsel before the class-action lead plaintiff deadline on September 22, 2025. Rosen, The First Filing Firm, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm